Paul A Wender, Age 77930 Siskiyou Dr, Menlo Park, CA 94025

6495663, Dec 17, 2002

Sep 14, 1999

09/396195

Jonathan B. Rothbard - Woodside CA
Paul A. Wender - Menlo Park CA

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

C07K 700

530329, 530324, 530325, 530326, 530327, 530328, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17

Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biological membrane, wherein a biological membrane is contacted with a conjugate containing a biologically active agent that is covalently attached to a transport polymer. In one embodiment, the polymer consists of from 6 to 25 subunits, at least 50% of which contain a guanidino or amidino sidechain moiety. The polymer is effective to impart to the attached agent a rate of trans-membrane transport across a biological membrane that is greater than the rate of trans-membrane transport of the agent in non-conjugated form.

6593292, Jul 15, 2003

Aug 24, 2000

09/648400

Jonathan B. Rothbard - Cupertino CA
Paul A. Wender - Menlo Park CA
P. Leo McGrane - Mountain View CA
Lalitha V. S. Sista - Sunnyvale CA
Thorsten A. Kirschberg - Mountain View CA

CellGate, Inc. - Sunnyvale CA

A61K 31496

514 2, 514 11, 514 12, 514 15, 514 16, 514 17, 514159, 514169, 51425407, 514263, 514291, 514423, 514456, 514458, 514634, 514635, 514636, 530300, 530321, 530328, 530329, 530330, 544366

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

6624189, Sep 23, 2003

Nov 30, 2000

09/728929

Paul A. Wender - Menlo Park CA
Blaise Lippa - Stonington CT
Cheol-Min Park - Gurnee IL
Kevin W. Hinkle - Chapel Hill NC

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

A61K 31335

514450, 514452, 514453, 514455, 514456, 540456, 549267

Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or imroved recognition domains are disclosed, including methods of preparing and utilizing the same.

6669951, Dec 30, 2003

Feb 23, 2001

09/792480

Jonathan B. Rothbard - Cupertino CA
Paul A. Wender - Menlo Park CA
P. Leo McGrane - Mountain View CA
Lalitha V. S. Sista - Sunnyvale CA
Thorsten A. Kirschberg - Mountain View CA

CellGate, Inc. - Sunnyvale CA

A61K 902

424436, 514 2, 514 11, 514 16, 514169, 514634, 514636, 530300, 530329, 564236, 564243

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

6730293, May 4, 2004

Aug 24, 2000

09/645689

Jonathan B. Rothbard - Cupertino CA
Paul A. Wender - Menlo Park CA
P. Leo McGrane - Mountain View CA
Lalitha V. S. Sista - Sunnyvale CA
Thorsten A. Kirschberg - Mountain View CA

CellGate, Inc. - Sunnyvale CA

A61K 31765

424 7805, 424 7817, 424 7837, 525 5411

This invention provides compositions and methods for enhancing delivery of glucocorticoids and ascomycins such as hydrocortisone, cyclosporin and FK506 across into and across one or more layers of the skin for the treatment of psoriasis and other inflammatory diseases of the skin.

6759387, Jul 6, 2004

Jul 30, 2002

10/209421

Jonathan B. Rothbard - Cupertino CA
Paul A. Wender - Menlo Park CA
P. Leo McGrane - Mountain View CA
Lalitha V. S. Sista - Sunnyvale CA
Thorsten A. Kirschberg - Mountain View CA

Cellgate, Inc. - Sunnyvale CA

A61K 31436

514 2, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 51425407, 514291, 514383, 514399, 540461, 544366, 5482666, 5483425

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:50).

7067698, Jun 27, 2006

Aug 2, 2002

10/211986

Paul A. Wender - Menlo Park CA, US
Christopher L. VanDeusen - Mountain View CA, US
Kanaka Pattabiraman - Menlo Park CA, US
Erin T. Pelkey - Phelps NY, US
Theodore C. Jessop - Palo Alto CA, US

The Board of Trustees of the Leland Stanford Junior University - Stanford CA

C07C 277/00

564236, 514 20, 514565, 554 53, 564230, 530333, 530345

Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of ω-amino groups to the corresponding guanidinyl groups. These compounds find utility as transport agents. Modified oligoguanidine compounds are also described.

7151116, Dec 19, 2006

Jan 13, 2004

10/757810

Paul A. Wender - Menlo Park CA, US
Orion D. Jankowski - Burlingame CA, US
Elie A. Tabet - Durham NC, US

Board of Trustees of The Leland Stanford Junior University - Stanford CA

A61K 31/35

514450, 549271, 548431

The invention provides novel apoptosis-inducing compounds that include isolated, purified isoapoptolidin, and selectively functionalized isoapoptolidin derivatives and stereoisomers thereof; selectively functionalized apoptolidin derivatives and stereoisomers thereof; and deglycosylated isoapoptolidin and selectively functionalized derivatives and stereoisomers thereof. The isoapoptolidin, apoptolidin, and deglycosylated isoapoptolidin derivatives may be functionalized by substituting any or all of the methoxyl or hydroxyl groups of the parent molecule. Pharmaceutical compositions and methods for using the compounds are also provided.